FindTrial
Sign In

Feasibility and safty of CDDP-Microsphea TACE in epirbicin or miriplatin TACE refractory HCC with Child-Pugh score<8 patients.

Feasibility and safty of CDDP-Microsphea TACE in epirbicin or miriplatin TACE refractory HCC with Child-Pugh score<8 patients. - CDDP-Microsphea TACE to epirbicin or miriplatin TACE refractory HCC

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017688
Enrollment
50
Registered
2015-05-27
Start date
2015-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

cisplatin,microsphea

Sponsors

Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Histologicaly or clinicaly confirmed HCC. (2)No indication of liver resection or RFA, PEI. (3)Epirbicin-TACE or Miripratin-TACE refractory HCC. (4)HCC without Vp3, Vp4, Vv2, Vv3,B3, B4. (5)HCC without extrahepatic lesion. (6)ECOG Performance Status 0-2 (7)Without dysfunction of liver, renal, coagulopathy. (8)Child-Pugh score<8 (9)Without administration of CDDP and Microsphea. (10)Written informed consent.

Exclusion criteria

Exclusion criteria: (1)Massive type or infiltrative type of HCC. (2)HCC supplied by extrahepatic artery. (3)No hypersensitivity to contrast medium. (4)Synchronous or metachronous malignancies within five years. (5)Pregnant, lacting women or women with suspected pregnancy. (6)Patients judged inappropriate for this study by physicians

Design outcomes

Primary

MeasureTime frame
Dose Limiting Toxicity and Recommended Dose—

Secondary

MeasureTime frame
Objective response rate and disease control rate, frequency and severity of adverse event at recommended dose.—

Countries

Japan

Contacts

Public ContactYuya Seko

Kyoto Prefectural University of Medicine Gastroenterology and Hepatology

yuyaseko@koto.kpu-m.ac.jp075-251-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026